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Abstract
Background: Adherence with medication taking is a major barrier to physiologic control in
diabetes and many strategies for improving adherence are in use. We sought to describe the use
of mnemonic devices and other adherence aids by adults with diabetes and to investigate their
association with control of hyperglycemia, hyperlipidemia and hypertension.
Methods:  Cross sectional survey of diabetic adults randomly selected from Primary Care
practices in the Vermont Diabetes Information System. We used linear regression to examine the
associations between the use of various aids and physiologic control among subjects who used oral
agents for hyperglycemia, hypercholesterolemia, and hypertension.
Results: 289 subjects (mean age 65.4 years; 51% female) used medications for all three conditions.
Adherence aids were reported by 80%. The most popular were day-of-the-week pill boxes (50%),
putting the pills in a special place (41%), and associating pill taking with a daily event such as a meal,
TV show, or bedtime (11%). After adjusting for age, sex, marital status, income, and education,
those who used a special place had better glycemic control (A1C -0.36%; P = .04) and systolic blood
pressure (-5.9 mm Hg; P = .05) than those who used no aids. Those who used a daily event had
better A1C (-0.56%; P = .01) than patients who used no aids.
Conclusion: Although adherence aids are in common use among adults with diabetes, there is
little evidence that they are efficacious. In this study, we found a few statistically significant
associations with adherence aids and better diabetes control. However, these findings could be
attributed to multiple comparisons or unmeasured confounders. Until more rigorous evaluations
are available, it seems reasonable to recommend keeping medicines in a special place for diabetic
adults prescribed multiple medications.
Background
Adherence has long been recognized to be a major barrier
to optimum care of chronic diseases, including diabetes
[1-3]. Typical rates of medication adherence are about
50%, with a very wide range [4,5]. Many approaches have
been offered to improve adherence including patient edu-
cation, written information, behavior modification, cash
incentives, directly observed therapy, and even incarcera-
tion [6-9]. Although medication-taking behavior has
many components, forgetfulness has been noted to be a
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major mechanism of non-adherence, especially in chronic
disease [3,10]. A number of maneuvers have been pro-
posed to enhance adherence, often by compensating for
poor memory [11]. These aids range from simple paper-
and-pencil checklists and calendars [12], to special pack-
aging with calendar blister packs, to sophisticated compu-
terized dispensing machines that pop open a small drawer
containing pills and signal the patient when a dose is due.
One of the earliest devices (patented in 1894) was a
printed clock face that was attached to medication bottles
to indicate when the next dose was due [13]. Recently,
home computers, e-mail, and personal paging systems
have appeared [14,15].
Data on the prevalence of adherence aids in clinical prac-
tice are unavailable for any condition, including diabetes.
Likewise, the efficacy of most of these devices is unstud-
ied. Calendar blister packs have been studied for infec-
tious diseases and hypertension, (with mixed results
[16,17]), but not, apparently, for diabetes. A variety of
educational and support interventions have been studied
for several other chronic conditions [18]. Again, the
results have been mixed and diabetes has not been not the
target condition.
Even modest increments in adherence could have sub-
stantial impacts upon clinical outcomes and costs [19-
21]. Adherence aids might not have to be widely success-
ful to be valuable. For instance, an intervention such as a
day-of-the-week pill box or a medication calendar, that
costs no more than a few dollars per patient, would be
cost-effective if it helped just one patient in hundreds
lower their A1C by just one percentage point. We are una-
ware of any systematic studies of either the prevalence or
effectiveness of adherence aids in diabetes.
Methods
As part of a larger study of diabetes, the Vermont Diabetes
Information System [22], we recruited 125 Primary Care
providers from 69 practices across Vermont, New Hamp-
shire, and upstate New York For this analysis, we ran-
domly selected adults with diabetes (confirmed by the
provider) from each practice. Patients whose provider
noted them to be severely demented or residing in a nurs-
ing home were eliminated. After receiving an introductory
letter from their provider, potential subjects were tele-
phoned and invited to participate in an interview at their
home.
Subjects who agreed were mailed a questionnaire and
were scheduled for an interview by a trained field inter-
viewer. The questionnaire covered multiple domains
including demographics, medication usage, and use of
adherence aids. The adherence aid items included a list of
known aids and asked the patients to record all that they
used. During the visit, the interviewer reviewed any miss-
ing or ambiguous questionnaire items. If necessary, the
interviewer read the questions aloud for subjects and
recorded their responses for them. Then the interviewer
measured the subjects' height and weight and blood pres-
sure (three times at five minute intervals). The subjects
were asked to produce every medicine (including prescrip-
tion, non-prescription, and over-the-counter medications,
herbal preparations, vitamins, and supplements) they had
used in the past month for the interviewer to record.
The local community hospital clinical laboratories pro-
vided the most recent measure of glycosolated hemo-
globin (A1C) and LDL-cholesterol for each subject.
We used basic descriptive statistics to describe the propor-
tion of subjects reporting use of the various aids. Blood
pressure was analyzed as the mean of the three recorded
systolic pressures. We used chi-square tests to compare
proportions and t-tests to compare means. For aids
reported by at least 10% of subjects, we calculated the lev-
els of physiologic control (mean A1C, mean LDL-choles-
terol, and mean systolic blood pressure) for those using
and not using the aid. The association of physiologic con-
trol with aid usage was evaluated with least-squares linear
regression. Because social and economic factors may be
associated with both adherence aid use and physiologic
control, we adjusted for potential confounders by expand-
ing the regression models to include covariates for patient
age, sex, income (in seven ordinal categories), education
(in seven ordinal categories), race ("white" or not) and
marital status ("currently married or living as such" or
not). We restricted the analysis to subjects who used oral
medications from all three classes under consideration
and had complete data on adherence use, physiologic
control, and socioeconomic status. Subjects who were
using only insulin without an oral hypoglycemic agent
were excluded.
The study protocol was approved by the University of Ver-
mont Committee for the Protection of Human Subjects
(CHRMS# 01–211) and was performed in full compliance
with the Helsinki Declaration. All interviewed subjects
provided fully informed consent.
Results
71% of contacted subjects agreed to the field survey. Of
1,007 interviewed subjects, 136 were interviewed before
the adherence aide questions were included in the survey,
526 were not using oral medications from all three classes,
and 56 had incomplete data. The average age of the 289
remaining subjects was 65.4 years with a range from 33 to
90 years; 51% were female. Seventy-two percent were high
school graduates; 16% finished at least a four year college
degree. Ninety-eight percent were white. The mean A1C atBMC Family Practice 2006, 7:1 http://www.biomedcentral.com/1471-2296/7/1
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the last measured value before the interview was 7.2%.
52% were under control (A1C <7.0%). The mean LDL was
96 mg/dl; 57% were below the target of 100 mg/dl. The
mean blood pressure was 143/78 mm Hg with 20% at
130/80 mm Hg or lower. The mean body mass index was
34.5 kg/m2 with 71% in the obese range (30 – 61 kg/m2).
All 289 subjects were using at least one oral agent for each
of hypertension, hypercholesterolemia, and hyperglyc-
emia. The average number of medications (including as-
needed preparations) was 10.5 with a range from 3 to 29.
Prescription medications accounted for 8.3 of these while
non-prescription preparations averaged 2.2 per subject.
Insulin was used by 16% of respondents.
The included subjects were similar to those not taking
medications from all three classes in terms of age, sex,
race, income, and education. As expected, they used more
medications (10.5 vs. 7.5; P < 0.001), and had higher A1C
(7.2 vs. 7.1%; P = 0.01), LDL-cholesterol (107 vs. 96 mg/
dl; P < 0.001), and systolic blood pressure measurements
(143 vs. 140 mm Hg; P = 0.07). Body mass index was also
higher in the included subjects (34.4 vs. 33.2 kg/m2; P =
0.01)
Two-hundred-thirty-one subjects (80%) reported using
one or more aids. One-hundred-thirty-two (46%)
reported one aid; 61 (21%) reported two aids, 29 (10%)
reported three aids; nine (3%) reported four or more aids.
The most popular aids were the day-of-the-week pill box
(50% of all respondents), keeping medicines in a special
place (41%), and associating medicines with a daily event
such as a TV show or meal (17%). See Table 1.
Among subjects who reported that "I put my pills in a spe-
cial place that reminds me," compared to those who used
no adherence aides, physiologic control was somewhat
better in all three areas: glycemic control (A1C = 7.05 vs.
7.44%; P = 0.03), systolic blood pressure (139.6 vs. 144.7
mmHg; P = 0.08), and LDL-cholesterol (93.8 vs. 94.4 mm/
dl; P = 0.90). After adjusting for possible social and eco-
nomic confounders, glycemic control and blood pressure,
but not hypercholesterolemia, were significantly better in
those who used the aide. See Table 2.
Among those who reported that "A daily event (a meal, TV
show, bedtime, brushing my teeth) reminds me," glyc-
emic control was significantly better than those who used
no aides (A1C = 6.87 vs. 7.44%; P = 0.005). However, the
Table 1: Use of various adherence aids in 289 adults with diabetes
Adherence Aid Number %
I use a day-of-the-week pill box 143 49.5
I put my pills in a special place that reminds me 117 40.5
A daily event (a meal, TV show, bedtime, brushing my teeth) reminds me 50 17.3
My family or friends remind me 27 9.3
I check off my medicines on a list 12 4.2
Someone gives me my medicines each time 10 3.5
I move the medicines from one place to another 93 . 1
I use an electronic pill box or dispenser 41 . 4
I mark a calendar or diary when I take my medicines 3 1.0
The pharmacy makes special packets of pills for each time I take my medicine 3 1.0
I set a timer 31 . 0
I leave a note for myself 31 . 0
My pager beeps to remind me 20 . 7
I move my watch or jewelry from one hand to the other 1 0.4
I receive a phone call to remind me 00
Any one or more of the above 231 79.9
37% of subjects reported using more than one adherence aid.
Table 2: Multivariate associations between adherence aid use and physiologic control in 289 adults with diabetes
Aid A1C Systolic Blood Pressure LDL-cholesterol
%P m m  H g P m g / d l P
Special place -0.36 .04 -5.9 .05 +0.4 .94
Daily event -0.56 .01 +1.5 .73 +0.6 .92
Pill box -0.11 .57 -2.9 .35 +7.2 .16
Any aid -0.24 .15 -3.5 .24 +3.0 .52
Linear regressions between adherence aid use and physiologic control adjusting for age, sex marital status, income, race, and education. A negative 
sign indicates that use of the aid was associated with a lower (better) value of the physiologic measure.BMC Family Practice 2006, 7:1 http://www.biomedcentral.com/1471-2296/7/1
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other physiologic domains were not significantly differ-
ent: systolic blood pressure (143.4 vs. 144.7 mmHg; P =
0.72), and LDL-cholesterol (95.8 vs. 94.4 mm/dl; P  =
0.81). The benefit for glycemic control and lack of efficacy
for blood pressure and cholesterol were confirmed in the
multivariate analyses. See Table 2.
About half of subjects indicated that "I use a day-of-the-
week pill box." Compared to those who used no aids,
there was no significant association with glycemic control
(A1C = 7.19 vs. 7.44%; P = 0.16), systolic blood pressure
(141.9 vs. 144.7 mmHg; P = 0.35) or LDL-cholesterol lev-
els (101.2 vs. 94.4 mm/dl; P = 0.17). Again, this pattern of
effect was not altered by multivariate adjustment for pos-
sible confounders (Table 2).
Users of any one or more aids had a mean A1C of 7.13%.
Among the non-users, the mean A1C was 7.44% (P  =
0.05). There was no significant advantage for aid users in
mean LDL level (97.0 vs. 94.4 mg/dl; P = 0.57) or systolic
blood pressure (142.0 vs. 144.7 mmHg; P = 0.37). In mul-
tivariate analyses, none of the physiologic risk factors
were significantly different between users and non-users.
See Table 2.
Discussion
A wide variety of adherence aids are in common use
among adults with diabetes. More than three quarters of
these subjects use one or more aids, with half using a day-
of-the-week pill box. A few aides were associated with bet-
ter physiologic control and these findings persisted when
adjusting for social and economic factors.
However, several limitations of this analysis should be
kept in mind. Subjects were not randomly assigned to the
use of aids. Therefore, the relationship between use of
adherence aids and physiologic control may be con-
founded by unmeasured variables. In other words, the
patients who use aids may have other behaviors or charac-
teristics that influence their laboratory results. For
instance, it is possible that patients who use mnemonic
devices for their medicines also tend to exercise and fol-
low their diet.
We performed three regression analyses on each of four
aides, raising the possibility of falsely declaring statistical
significance when no association exists (Type I error due
to multiple comparisons). If we raise the threshold for sig-
nificance with the Bonferroni correction to 0.05/12 =
0.0042 [23], none of the analyses demonstrate statistical
significance.
Patients with diabetes receiving care in mostly rural pri-
mary care practices were randomly invited to participate
in the study. Our results may not generalize to popula-
tions from other settings. In particular, this population is
primarily older adults with Type 2 diabetes using multiple
prescription medications. These results may not generaliz-
able to diabetic patients on simpler regimens or patients
with other chronic conditions. Further, it is possible that
patients who consented to the interview are systematically
different than refusers in regard to their use of adherence
aids.
Conclusion
Medication adherence remains an important barrier to
optimum patient care [24]. Although adherence aids are
in common use among adults with diabetes, there is little
evidence that they are efficacious. In this study, a few asso-
ciations with better control were observed, but they may
be artifacts of multiple comparisons or unmeasured con-
founders. Until more rigorous evaluations are available, it
seems reasonable to recommend keeping medicines in a
special place for diabetic adults prescribed multiple med-
ications.
Competing interests
The author(s) declare that they have no competing inter-
ests.
Authors' contributions
BL conceptualized the study, performed the analysis, and
drafted the manuscript. CDM contributed to the design
and analysis, supervised the data collection, and edited
the manuscript. LH made major analytical and design
contributions and edited the manuscript. All authors read
and approved the final manuscript.
Acknowledgements
This work was funded by the National Institute of Diabetes and Digestive 
and Kidney Diseases (R01 DK61167 and K24 DK068380).
References
1. Watkins JD, Roberts DE, Williams TF, Martin DA, Coyle IV: Obser-
vation of medication errors made by diabetic patients in the
home.  Diabetes 1967, 16:882-5.
2. Cerkoney AB, Hart K: The relationship between the health
belief model and compliance of persons with diabetes melli-
tus.  Diabetes Care 1980, 3:594-8.
3. Cramer JA, Spilker B: Patient Compliance in Medical Practice and Clinical
Trials New York: Raven Press; 1991. 
4. Haynes RB, Taylor DW, Sackett DL: Compliance in Health Care Balti-
more: Johns Hopkins University Press; 1979. 
5. Schectman JM, Bovbjerg VE, Voss JD: Predictors of medication-
refill adherence in an indigent rural population.  Med Care
2002, 40:1294-300.
6. Roter DL, Hall JA: Strategies for enhancing patient adherence
to medical recommendations.  JAMA 1994, 271:80.
7. Warren L, Hixenbaugh P: Adherence and Diabetes.  In Adherence
to Treatment in Medical Conditions Edited by: Meyers LB, Midence K.
Amsterdam: Harwood; 1998:423-453. 
8. Chee CB, James L: The Singapore Tuberculosis Elimination
Programme: the first five years.  Bull WHO 2003, 81:217-21.
9. White MC, Tulsky JP, Reilly P, McIntosh HW, Hoynes TM, Goldenson
J: A clinical trial of a financial incentive to go to the tubercu-
losis clinic for isoniazid after release from jail.  Int J Tuberculosis
Lung Dis 1998, 2:506-12.Publish with BioMed Central    and   every 
scientist can read your work free of charge
"BioMed Central will be the most significant development for 
disseminating the results of biomedical research in our lifetime."
Sir Paul Nurse, Cancer Research UK
Your research papers will be:
available free of charge to the entire biomedical community
peer reviewed and published  immediately upon acceptance
cited in PubMed and archived on PubMed Central 
yours — you keep the copyright
Submit your manuscript here:
http://www.biomedcentral.com/info/publishing_adv.asp
BioMedcentral
BMC Family Practice 2006, 7:1 http://www.biomedcentral.com/1471-2296/7/1
Page 5 of 5
(page number not for citation purposes)
10. Levy RL, Loftus GR: Compliance and memory.  In Everyday Mem-
ory: Actions and Absent-mindedness Edited by: Harris JE, Harris PE. New
York: Academic Press; 1984. 
11. Meichenbaum D, Turk DC: Facilitating Treatment Adherence New
York: Plenum; 1987:138-46. 
12. Raynor DK, Booth TG, Blenkinsopp A: Effects of computer gen-
erated reminder charts on patients' compliance with drug
regimens.  BMJ 1993, 306:1158-1161.
13. Worthen DB: Medicine Timer.  Journal of the American Pharmacists
Association 2004, 44:374.
14. Weintraub A: Make your PDA a health partner.  Business Week
:138-140. October 7, 2002
15. Milch RA, Ziv L, Evans V, Hillebrand M: The effect of an alphanu-
meric paging system on patient compliance with medicinal
regimens.  Am J Hosp Palliat Care 1996, 13:46-48.
16. Yeboah-Antwi K, Gyapong JO, Asare IK, Barnish G, Evans DB, Adjei
S:  Impact of prepackaging antimalarial drugs on cost to
patients and compliance with treatment.  Bull WHO 2001,
79:394-399.
17. Becker LA, Glanz K, Sobel E, Mossey J, Zinn SL, Knott KA: A rand-
omized trial of special packaging of antihypertensive medi-
cations.  J Fam Pract 1986, 22:357-361.
18. Haynes RB, McKibbon KA, Kanani R: Systematic review of rand-
omized trials of interventions to assist patients to follow pre-
scriptions for medications.  Lancet 1996, 348:383-6.
19. Gilmer TP, O'Connor PJ, Manning WG, Rush WA: The cost to
health plans of poor glycemic control.  Diabetes Care 1997,
20:1847-53.
20. Testa MA, Simonson DC: Health economic benefits and quality
of life during improved glycemic control in patients with type
2 diabetes: a randomized, controlled, double-blind trial.
JAMA 1998, 280:1490-6.
21. Wagner EH, Sandhu N, Newton KM, McCulloch DK, Ramsey SD,
Grothaus LC: Effect of improved glycemic control on health
care costs and utilization.  JAMA 2001, 285:182-189.
22. MacLean CD, Littenberg B, Gagnon M, Reardon M, Turner P, Jordan
C: The Vermont Diabetes Information System (VDIS): study
design and subject recruitment for a cluster randomized
trial of a diabetes registry in a statewide sample of primary
care practices.  Clinical Trials 2004, 1:532-544.
23. Bland JM, Altman DG: Multiple significance tests: the Bonfer-
roni method.  BMJ 1995, 310(6973):170.
24. Osterberg L, Blaschke T: Drug Therapy: Adherence to medica-
tion.  N Engl J Med 2005, 353:487-97.
Pre-publication history
The pre-publication history for this paper can be accessed
here:
http://www.biomedcentral.com/1471-2296/7/1/prepub